Redhill Biopharma Stock Fundamentals
| RDHL Stock | USD 0.43 0.01 2.27% |
Redhill Biopharma fundamentals help investors to digest information that contributes to Redhill Biopharma's financial success or failures. It also enables traders to predict the movement of Redhill Stock. The fundamental analysis module provides a way to measure Redhill Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Redhill Biopharma stock.
At this time, Redhill Biopharma's Net Income is quite stable compared to the past year. Gross Profit is expected to rise to about 5.1 M this year, although the value of Selling General Administrative will most likely fall to about 18.4 M. Redhill | Select Account or Indicator |
Redhill Biopharma Company Return On Equity Analysis
Redhill Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Redhill Biopharma Return On Equity | -8.84 |
Most of Redhill Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Redhill Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Redhill Biopharma has a Return On Equity of -8.8429. This is 63.11% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Redhill Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Redhill Biopharma's current stock value. Our valuation model uses many indicators to compare Redhill Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Redhill Biopharma competition to find correlations between indicators driving Redhill Biopharma's intrinsic value. More Info.Redhill Biopharma is rated fifth in return on equity category among related companies. It is rated fifth in return on asset category among related companies . At this time, Redhill Biopharma's Return On Equity is quite stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Redhill Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Redhill Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Redhill Biopharma's earnings, one of the primary drivers of an investment's value.Redhill Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Redhill Biopharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Redhill Biopharma could also be used in its relative valuation, which is a method of valuing Redhill Biopharma by comparing valuation metrics of similar companies.Redhill Biopharma is currently under evaluation in return on equity category among related companies.
Redhill Fundamentals
| Return On Equity | -8.84 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | 3.66 % | ||||
| Operating Margin | (10.61) % | ||||
| Current Valuation | 3.48 B | ||||
| Shares Outstanding | 31.87 M | ||||
| Shares Owned By Institutions | 6.24 % | ||||
| Number Of Shares Shorted | 906.88 K | ||||
| Price To Earning | (3.67) X | ||||
| Price To Book | 6.55 X | ||||
| Price To Sales | 2.08 X | ||||
| Revenue | 6.51 M | ||||
| Gross Profit | 45.25 M | ||||
| EBITDA | (29.37 M) | ||||
| Net Income | 23.85 M | ||||
| Cash And Equivalents | 28.86 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 1.17 M | ||||
| Debt To Equity | 9.89 % | ||||
| Current Ratio | 0.98 X | ||||
| Book Value Per Share | 0.10 X | ||||
| Cash Flow From Operations | (35.73 M) | ||||
| Short Ratio | 1.12 X | ||||
| Earnings Per Share | 4.00 X | ||||
| Target Price | 760.0 | ||||
| Number Of Employees | 53 | ||||
| Beta | 3.46 | ||||
| Market Capitalization | 14.1 M | ||||
| Total Asset | 23.05 M | ||||
| Retained Earnings | (407.74 M) | ||||
| Working Capital | (3.1 M) | ||||
| Current Asset | 60.51 M | ||||
| Current Liabilities | 5.51 M | ||||
| Net Asset | 23.05 M |
About Redhill Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Redhill Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Redhill Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Redhill Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 0.90 | 0.86 | |
| Total Revenue | 6.5 M | 6.2 M | |
| Cost Of Revenue | 3.5 M | 3.3 M | |
| Stock Based Compensation To Revenue | 0.25 | 0.24 | |
| Sales General And Administrative To Revenue | 4.43 | 4.21 | |
| Research And Ddevelopement To Revenue | 0.54 | 0.51 | |
| Capex To Revenue | (0) | (0) | |
| Revenue Per Share | 1.01 | 0.96 | |
| Ebit Per Revenue | (4.81) | (5.05) |
Currently Active Assets on Macroaxis
When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:Check out Redhill Biopharma Piotroski F Score and Redhill Biopharma Altman Z Score analysis. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Redhill Stock analysis
When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 4 | Revenue Per Share 1.008 | Quarterly Revenue Growth (0.96) | Return On Assets (0.16) | Return On Equity (8.84) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.